A citation-based method for searching scientific literature

Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S Sabatine. Lancet 2019
Times Cited: 856



Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann, Waheed Jamal, Karen Kimura, Janet Schnee, Cordula Zeller, Daniel Cotton, Edimar Bocchi, Michael Böhm, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure, Nadia Giannetti, Stefan Janssens, Jian Zhang, Jose R Gonzalez Juanatey, Sanjay Kaul, Hans-Peter Brunner-La Rocca, Bela Merkely, Stephen J Nicholls, Sergio Perrone, Ileana Pina, Piotr Ponikowski, Naveed Sattar, Michele Senni, Marie-France Seronde, Jindrich Spinar, Iain Squire, Stefano Taddei, Christoph Wanner, Faiez Zannad. N Engl J Med 2020
Times Cited: 383




List of shared articles



Times cited

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
Pardeep S Jhund, Scott D Solomon, Kieran F Docherty, Hiddo J L Heerspink, Inder S Anand, Michael Böhm, Vijay Chopra, Rudolf A de Boer, Akshay S Desai, Junbo Ge,[...]. Circulation 2021
23

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, Muhammad Shahzeb Khan, Nikolaus Marx, Carolyn S P Lam, Sven Schnaidt, Anne Pernille Ofstad, Martina Brueckmann, Waheed Jamal,[...]. Circulation 2021
17


Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.
Ronald M Goldenberg, Vineeta Ahooja, Kristin K Clemens, Jeremy D Gilbert, Megha Poddar, Subodh Verma. Can J Diabetes 2021
1

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
5

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod,[...]. N Engl J Med 2021
52

SGLT2-inhibitors; more than just glycosuria and diuresis.
Amir Fathi, Keeran Vickneson, Jagdeep S Singh. Heart Fail Rev 2021
2

Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure.
Julius L Katzmann, Amy M Mason, Winfried März, Marcus E Kleber, Alexander Niessner, Matthias Blüher, Thimoteus Speer, Ulrich Laufs. Clin Pharmacol Ther 2021
0

Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Matthias Rau, Kirsten Thiele, Niels-Ulrik Korbinian Hartmann, Alexander Schuh, Ertunc Altiok, Julia Möllmann, András P Keszei, Michael Böhm, Nikolaus Marx, Michael Lehrke. Cardiovasc Diabetol 2021
1


SCORED and SOLOIST: the next scores for SGLT2 inhibitors.
Johann Bauersachs. Cardiovasc Res 2021
0

Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun.
Pantelis Sarafidis, Alberto Ortiz, Charles J Ferro, Jean-Michel Halimi, Reinhold Kreutz, Francesca Mallamaci, Giuseppe Mancia, Christoph Wanner. J Hypertens 2021
0

Immuno-metabolic interfaces in cardiac disease and failure.
Edoardo Bertero, Jan Dudek, Clement Cochain, Murilo Delgobo, Gustavo Ramos, Brenda Gerull, Takahiro Higuchi, Martin Vaeth, Alma Zernecke, Stefan Frantz,[...]. Cardiovasc Res 2021
1

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.
Benedetta Maria Bonora, Emanuel Raschi, Angelo Avogaro, Gian Paolo Fadini. Cardiovasc Diabetol 2021
1

Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
Jasper Tromp, Piotr Ponikowski, Afshin Salsali, Christiane E Angermann, Jan Biegus, Jon Blatchford, Sean P Collins, João Pedro Ferreira, Claudia Grauer, Mikhail Kosiborod,[...]. Eur J Heart Fail 2021
2

The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
Michelle L O'Donoghue, Eri T Kato, Ofri Mosenzon, Sabina A Murphy, Avivit Cahn, Marisol Herrera, Tsvetalina Tankova, Alena Šmahelová, Piera Merlini, Ingrid Gause-Nilsson,[...]. Diabetologia 2021
0

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.
Avivit Cahn, Itamar Raz, Lawrence A Leiter, Ofri Mosenzon, Sabina A Murphy, Erica L Goodrich, Ilan Yanuv, Aliza Rozenberg, Deepak L Bhatt, Darren K McGuire,[...]. Diabetes Care 2021
0

Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.
Edimar Alcides Bocchi, Andréa Biolo, Lidia Zytynski Moura, José Albuquerque Figueiredo Neto, Carlos Eduardo Lucena Montenegro, Denilson Campos de Albuquerque. Arq Bras Cardiol 2021
0

Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin.
Ricardo Fontes-Carvalho, Diogo Santos-Ferreira, Itamar Raz, Nikolaus Marx, Frank Ruschitzka, Francesco Cosentino. Eur J Prev Cardiol 2021
0